Cannabinoids show promise for Tourette syndrome but rigorous evidence is nearly nonexistent

There is a strong biological rationale for cannabinoid effects on tics, and many patients report improvement with cannabis. However, only two small randomized, placebo-controlled trials of THC have been published, and these merely suggested possible benefits. Trials of other cannabinoid agents are ongoing. The authors recommend restricting clinical use to adults given developmental risks.

Comprehensive literature search of PubMed for randomized controlled trials and clinical trials of cannabis-derived medications in Tourette syndrome. Extracted population, intervention, safety, and outcome data.

Tourette syndrome has limited pharmacological options, and many patients report cannabis helps their tics. But the evidence base consists of just two small trials, creating a gap between patient experience and clinical guidance.

Tourette syndrome is a textbook case of the cannabinoid evidence gap: strong biological plausibility, consistent patient reports, but almost no rigorous trial data. The field needs larger trials before clinical recommendations can be made.

Extremely limited trial data. Only THC has been tested in RCTs, not CBD or other cannabinoids. Safety profile is largely unknown in this population. Developmental effects of cannabinoids in children with Tourette syndrome are a concern.